La presentazione è in caricamento. Aspetta per favore

La presentazione è in caricamento. Aspetta per favore

M.Verri U.O. Anestesia e Rianimazione Universitaria Dir.Prof.R.Alvisi.

Presentazioni simili

Presentazione sul tema: "M.Verri U.O. Anestesia e Rianimazione Universitaria Dir.Prof.R.Alvisi."— Transcript della presentazione:

1 M.Verri U.O. Anestesia e Rianimazione Universitaria Dir.Prof.R.Alvisi

2 Riconoscimento che qualche cosa non va alterazione del sensorio dispnea, tachipnea, alterazione della meccanica-dinamica ventilatoria SpO 2 alterazione della PA tachicardia, aritmia contrazione della diuresi T° alterazione degli esami ematochimici ecc. quanto sopra + iper-ipotermia / leucocitosi-leucopenia infezione Quanto non va ? Valutazione della gravità giudizio personale scale di gravità sepsi, sepsi grave, shock settico

3 Tachicardia Ipotensione CVP PAOP Ittero Enzimi Albumina PT Stato di coscienza alterato, confusione, psicosi FR > 20 atti/m PaO2 < 70 mm Hg SaO2 < 90% PaO2/FiO2 300 Oliguria Anuria Creatinina Piastrine PT/APTT Proteina C D-dimero SOFA ?

4 Modified Early Warning Score Cut-off >4 Subbe CP et al Q J Med 2001; 94: 521-526 Goldhill DR et al Anaesthesia 2005; 60: 547-553 Patient-At-Risk warning score

5 Score1234 SNC GCS 13-1410-126-9<6 RESPIRATORIO Pa/FiO 2 (mmHg) < 400< 300< 200 con supporto resp < 100 CARDIOVASCOLA RE Ipotensione MAP < 70 mmHg Dopa < 5 o DObutamin a Dopa > 5 o Adr < 0,1 o Noradr < 0,1 Dopa > 15 Adr > 0,1 Noradr > 0,1 COAGULAZIONE Piastrine(10 3 /mm 3 ) < 150<100<50<20 FEGATO Bilirubina(mg/dl) 1,2-1,92,0-5,96,0-11,9>12 RENALE Creat (mg/dl) o Diur 1,2-1,92,0-3,43,5-4,9 o < 500 ml/24h > 5,0 < 200 ml/24 h Sequential Organ Failure Assessment (SOFA) Vincent JL, et al. Intensive Care Med 1996;22:707-10

6 S.C 37 aa endocardite embolizzazione shock (settico?) coma ascessi cerebrali ipoperfusione ipossia Riconoscimento gravità Supporto delle funzioni vitali Terapia eziologica Prevenzione complicanze insuff.respiratoria cardiopatia

7 Sapere Sapere fare (efficacia?) Efficienza Economicità Etica Allocazione risorse sicurezza

8 microbiologia antibioticoterapia rimozione sorgente Ottimizzazione perfusione volemia cristalloidi colloidi emocomponenti emoderivati tono vascolare vasocostrittori vasodilatatori ?? contrattilità miocardica dobutamina (dopamina) supporto respiratorio sostituz.funzione renale controllo glicemico nutrizione sedazione prevenzione complicanze ecc. steroidi ? Coupled Plasma Filtration Adsorption CPFA sono guarito !!! ECMO

9 Special admission paths: sepsis R Ferrer, A.Navas, ML Martinez, A.Artigas Barochia AV, Cui X, Vitberg D, Suffredini AF, OGrady NP, Banks SM. Bundled care for septic shock: an analysis of clinical trial. Crit Care Med 2010; 38(2).668-78 Ferrer R, Artigas A, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180(9):861-6 Levy MM, Dellinger RP, Bion J. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010;36(2):222-31 The key to success involves the implementation of a hospital wide system that recognizes septic patients early, and at the same time rapidly administers effective therapy ( sepsis-rapid response team)(?) The results of the meta-analysis are very consistent in showing that sepsis bundles improve survival by improving the way sepsis treatments are delivered Health care organizations traditionally favour investing in new technology and drugs, but are reluctant to invest in organizational development. For sepsis care bundles to succeed, this must change

10 Sepsis is very complex! Infectious agent? Pro inflammatory mediator early inhibitors Receptor activation Other factors? Pro- inflammatory mediators Signal pathway activation Anti- inflammatory mediators inhibitorsProtein synthesis Coagulation cascade Inflammatory cascade ROS Da EMC 2010

11 Immunoinflammatory response of three hypothetical patients with sepsis.

12 microbiologia antibioticoterapia rimozione sorgente Ottimizzazione perfusione volemia cristalloidi colloidi emocomponenti emoderivati tono vascolare vasocostrittori vasodilatatori ?? contrattilità miocardica dobutamina (dopamina) supporto respiratorio sostituz.funzione renale controllo glicemico nutrizione sedazione prevenzione complicanze ecc. steroidi ? Coupled Plasma Filtration Adsorption CPFA ECMO






18 Cardiac conditions considered to increase a patients risk of developing infective endocarditis, i.e. at risk heart valve lesions.

19 The endocarditis risk in GUCH patients is substantially higher than in the general population, with marked variation between lesions. It has to be emphasized that good oral hygiene and regular dental review have an essential role in reducing the risk of IE. Aseptic measures are mandatory during manipulation of venous catheters and during any invasive procedure in order to reduce the rate of healthcare-associated IE. GUCH patients should also be discouraged from getting piercings and tattoos.

20 The approach to antibiotic endocarditis prophylaxis has changed for several reasons. In short, transient bacteraemia occurs not only after dental procedures but frequently in the context of daily routine activities such as tooth brushing, flossing, or chewing. Due to the lack of scientific evidence for the efficacy of antibiotic prophylaxis, the estimated huge number of patients that may need to be treated to prevent one single case of IE, the small but existing risk of anaphylaxis, and the general problem of emergence of resistant microorganisms resulting from widespread, often inappropriate use of antibiotics, it is currently recommended by expert consensus to limit antibiotic prophylaxis to patients with the highest risk of IE undergoing the highest risk procedures (IIaC).

21 This recommendation includes the following patient groups: Patients with a prosthetic valve or a prosthetic material used for cardiac valve repair Patients with previous IE Patients with CHD: a cyanotic CHD, without surgical repair, or with residual defects, palliative shunts, or conduits a CHD after repair with prosthetic material whether placed by surgery or by percutaneous technique, up to 6 months after the procedure (until endothelialization) a when a residual defect persists at the site of implantation of a prosthetic material or device by cardiac surgery or percutaneous technique. The recommendation is limited to dental procedures requiring manipulation of the gingival or periapical region of the teeth or perforation of the oral mucosa. Antibiotics are not recommended for respiratory tract, gastrointestinal, genitourinary, dermatological, or musculoskeletal procedures unless there is an established infection.






27 Steroids Consider intravenous hydrocortisone for adult septic shock when hypotension remains poorly responsive to adequate fluid resuscitation and vasopressors. (2C) ACTH stimulation test is not recommended to identify the subset of adults with septic shock who should receive hydrocortisone. (2B) Hydrocortisone is preferred to dexamethasone. (2B) Fludrocortisone (50μg orally once a day) may be included if an alternative to hydrocortisone is being used which lacks significant mineralocorticoid activity. Fludrocortisone is optional if hydrocortisone is used. (2C) Steroid therapy may be weaned once vasopressors are no longer required. (2D) Hydrocortisone dose should be 300 mg/day. (1A) Do not use corticosteroids to treat sepsis in the absence of shock unless the patients endocrine or corticosteroid history warrants it. (1D)

28 Steroids Negli ultimi anni luso dei corticosteroidi nello shock settico è risultato controverso Pro: – miglioramento emodinamico con più rapida sospensione dei vasopressori – > rapidità di risoluzione della disfunzione dorgano – < mortalità (?) Con: – mortalità tra responder e non responder – = rapidità nella sospensione dei vasopressori – > superinfezioni – debolezza neuromuscolare – intolleranza glucidica Nov.2008

29 Annane D, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862- 870 – Sì steroidi nello shock settico che richiede vasopressori SprungCL, et al. The CORTICUS randomized, double-blind, placebo- controlled study of hydrocortisone therapy in patients with septic shock. N Engl J Med 2008;358:111-124 – NO steroidi nello shock settico Steroids

30 Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine Crit Care Med 2008; 36:1937–1949 Recommendation 6: Hydrocortisone should be considered in the management strategy of patients with septic shock, particularly those patients who have responded poorly to fluid resuscitation and vasopressor agents. Strength of Recommendations: 2B

31 Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults Annane D, Bellissant E, Bollaert PE, et al. JAMA. 2009; 301:2362-2375 28-day mortality was modestly reduced (relative risk [RR] = 0.84, P =.05) and was also modestly reduced in the subset of studies reporting prolonged corticosteroid administration (RR = 0.84, P =.02). Treatment increased the proportion of patients achieving reversal of shock and reduced the length of intensive care unit stay without a detectable increase in gastrointestinal bleeding, superinfection, or neuromuscular complications. Corticosteroids did increase the risk for hyperglycemia and hypernatremia. The authors concluded that the prolonged use of corticosteroids safely reduces short- term mortality in patients with severe sepsis or septic shock. Until a definitive clinical trial answers this question, corticosteroid use will continue to be highly variable and at the discretion of intensivists worldwide

32 Conclusions: Based on clinically meaningful thresholds (RRR[15–25%) for mortality reduction in severe sepsis or septic shock, the Bayesian approach to all three meta-analyses consistently showed that low-dose steroids were not associated with survival benefits. The probabilities of developing steroid- induced side effects (superinfections, bleeding, and hyperglycemia) were high for all analyses.

33 Conclusion Patients randomized to treatment with hydrocortisone demonstrated a faster decrease in total organ dysfunction/failure determined by the SOFA score, primarily driven by a faster improvement in cardiovascular organ dysfunction/failure. This organ dysfunction/failure improvement was not accompanied by a decreased mortality. R. Moreno C. L. Sprung D. Annane S. Chevret J. Briegel D. Keh M. Singer Y. G. Weiss D. Payen B. H. Cuthbertson J.-L. Vincent

34 Ideal therapy for sepsis Plasma Reinfusate in UF out bad molecules good molecules SIRS = Systemic inflammatory response syndrome CARS = Compensatory anti-inflammatory response syndrome Hyper-inflammation Normal Immunoparalysis

35 CPFA used successfully in non-ARF patients Hemodynamic response to coupled plasmafiltration-adsorption in human septic shock Marco Formica, Carlo Olivieri, Sergio Livigni, Giulio Cesano, Antonella Vallero, Mariella Maio and Ciro Tetta Intensive Care Med (2003) 29: 703-708 Objective: The objective was to examine the effect of repeated applications of coupled plasmafiltration-adsorption on the hemodynamic response in septic shock patients hospitalized in intensive care units (ICUs). Conclusion: Coupled plasmafiltration-adsorption was a feasible and safe extracorporeal treatment and exerted a remarkable improvement in the hemodynamics, the pulmonary function, and the outcome in septic shock patients with or without concomitant ARF.

36 Anne-Corne´lie J. M. de Pont, MD, PhD Adult Intensive Care Unit Academic Medical Center University of Amsterdam Amsterdam, The Netherlands …The improvement of blood purification techniques and membranes has generated new opportunities for the use of extracorporeal techniques in sepsis. Removal of both pro- and anti-inflammatory mediators by means of these new techniques is feasible and might add to the restoration of homeostasis by controlling excessive cytokine production (the so-called peak concentration hypothesis). Whether this approach will result in a better clinical outcome for patients with severe sepsis remains to be investigated.

37 clinica tecnica organizzazione gestione

38 clinica tecnica organizzazione gestione

39 clinica tecnica organizzazione gestione economicità


41 Overall Conclusions CPFA appears to be a safe and well-tolerated treatment for treatment of septic patients CPFA improved hemodynamics, reduced some pro- and anti- inflammatory cytokines and restored immune balance More clinical studies are needed to determine target septic patient population and treatment indications

42 microbiologia antibioticoterapia rimozione sorgente Ottimizzazione perfusione volemia cristalloidi colloidi emocomponenti emoderivati tono vascolare vasocostrittori contrattilità miocardica dobutamina supporto respiratorio sostituz.funzione renale controllo glicemico nutrizione sedazione prevenzione complicanze ecc. steroidi ? proteina C attivata ricombinante ? (Drotrecogin) sono guarito !!!

43 Da Intensive Care Med 2010;36(12): 2019-2029

44 Indications for echocardiography in suspected infective endocarditis. IE, infective endocarditis; TTE, transthoracic echocardiography; TOE, transoesophageal echocardiography. TOE is not mandatory in isolated right-sided native valve IE with good quality TTE examination and unequivocal echocardiographic findings.

Scaricare ppt "M.Verri U.O. Anestesia e Rianimazione Universitaria Dir.Prof.R.Alvisi."

Presentazioni simili

Annunci Google